Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Gains from Sales and Divestitures (2020 - 2025)

Phibro Animal Health (PAHC) has 2 years of Gains from Sales and Divestitures data on record, last reported at $30000.0 in Q2 2025.

  • For Q2 2025, Gains from Sales and Divestitures changed N/A year-over-year to $30000.0; the TTM value through Jun 2025 reached $30000.0, changed N/A, while the annual FY2025 figure was $30000.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $30000.0 in Q2 2025 per PAHC's latest filing, roughly flat from $30000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $30000.0 in Q1 2025 and bottomed at $30000.0 in Q1 2025.